Nuvation Bio Inc. (NUVB) Reports Q3 Loss, Beats Revenue EstimatesZacks Investment Research • Wednesday
Nuvation Bio Reports Third Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire • Wednesday
Nuvation Bio to Present Additional Updated Phase 2 Results at 2026 Society for Neuro-Oncology Annual MeetingPRNewsWire • Monday
Nuvation Bio to Expand Pivotal Phase 3 SIGMA Study of Safusidenib for IDH1-Mutant Glioma to Six European CountriesPRNewsWire • 10/29/26
Nuvation Bio to Report Third Quarter 2026 Financial Results and Provide Business Update on November 4, 2026PRNewsWire • 10/21/26
Nuvation Bio Announces FDA Approval of Supplemental New Drug Application for IBTROZI® (taletrectinib) with Updated Duration of Response in TKI-Naïve Advanced ROS1-Positive Non-Small Cell Lung CancerPRNewsWire • 09/17/26
Nuvation Bio Inc. (NUVB) Presents at 12th Annual Cantor Fitzgerald Global Healthcare Conference TranscriptSeeking Alpha • 09/15/26
Nuvation Bio Announces New Analyses Reinforcing the Durable, Consistent Efficacy of IBTROZI® (taletrectinib) Across Key Patient Subgroups in Advanced ROS1+ NSCLC at 2026 World Conference on Lung CancerPRNewsWire • 09/15/26
Nuvation Bio Inc. (NUVB) Presents at Citigroup's Biopharma Back to School Summit 2026 TranscriptSeeking Alpha • 09/09/26
Does Nuvation Bio (NUVB) Have the Potential to Rally 91.92% as Wall Street Analysts Expect?Zacks Investment Research • 09/03/26
Nuvation: Why I'm Downgrading To Hold Despite Progress On NSCLC And Glioma FrontsSeeking Alpha • 08/26/26
Nuvation Bio Granted FDA Fast Track Designation for Safusidenib for Treatment of IDH1-Mutant GliomaPRNewsWire • 08/20/26
Wall Street Analysts Predict a 105.71% Upside in Nuvation Bio (NUVB): Here's What You Should KnowZacks Investment Research • 08/18/26
Nuvation Bio Inc. (NUVB) Reports Q2 Loss, Beats Revenue EstimatesZacks Investment Research • 08/06/26
Nuvation Bio Reports Second Quarter 2026 Financial Results and Provides Business UpdatePRNewsWire • 08/06/26
Nuvation Bio to Present New Subgroup Analyses of Pivotal Data for IBTROZI® (taletrectinib) in Advanced ROS1-Positive Non-Small Cell Lung Cancer at WCLC and ESMO Annual CongressesPRNewsWire • 08/04/26
Nuvation Bio Inc. (NUVB) Expected to Beat Earnings Estimates: Should You Buy?Zacks Investment Research • 07/30/26
Wall Street Analysts See a 94.32% Upside in Nuvation Bio (NUVB): Can the Stock Really Move This High?Zacks Investment Research • 07/29/26
Nuvation Bio to Report Second Quarter 2026 Financial Results and Provide Business Update on August 6, 2026PRNewsWire • 07/22/26